Additional Autoimmune Diseases With Type 1 Diabetes in Pediatrics at Diabetes Diagnosis and During Follow-up (AADT1D)
Additional Autoimmune Diseases With Type 1 Diabetes in Children and Adolescents at Diabetes Diagnostic and During Follow-up : a Monocentric Study in France
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Locations
-
-
Lorraine
-
Vandoeuvre les nancy, Lorraine, France, 54500
- Hopital D'Enfants de Brabois
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients with type 1 diabetes diagnosed with the following criteria: (i) Classic symptoms of diabetes or hyperglycemic crisis, with plasma glucose concentration ≥11.1 mmol/L (200 mg/dl), or (ii) fasting plasma glucose ≥7.0 mmol/l (≥126 mg/dl) ; and (iii) presence of diabetes associated autoantibodies : ICA, GAD, IA2, IAA and/or ZnT8
- age < 18 years old at type 1 diabetes diagnostic
- type 1 diabetes diagnosed between 2014-01-01 and 2021-02-01
Exclusion Criteria:
- type 1 diabetes diagnostic not certain
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of additional autoimmune diseases at type 1 diabetes diagnosis
Time Frame: up to 3 weeks after type 1 diabetes diagnosis
|
Will be studied the additional autoimmune diseases to type 1 diabetes listed in the 2018 ISPAD recommendations
|
up to 3 weeks after type 1 diabetes diagnosis
|
|
Type of additional autoimmune diseases at type 1 diabetes diagnosis
Time Frame: up to 3 weeks after type 1 diabetes diagnosis
|
Will be studied the additional autoimmune diseases to type 1 diabetes listed in the 2018 ISPAD recommendations
|
up to 3 weeks after type 1 diabetes diagnosis
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Characteristics of patients, if additional autoimmune disease is present or absent
Time Frame: up to 3 weeks after type 1 diabetes diagnosis
|
Family and personal history, biological, serological, anthropometrical characteristics at type 1 diabetes diagnostic
|
up to 3 weeks after type 1 diabetes diagnosis
|
|
Occurence or non-occurence of at least one additional autoimmune diseases during follow-up
Time Frame: From type 1 diabetes diagnostic to last news date, an average of 3 years
|
Will be studied the additional autoimmune diseases to type 1 diabetes listed in the 2018 ISPAD recommendations
|
From type 1 diabetes diagnostic to last news date, an average of 3 years
|
|
Occurence or non-occurence of each type of additional autoimmune disease during follow-up
Time Frame: From type 1 diabetes diagnostic to last news date, an average of 3 years
|
Will be studied the additional autoimmune diseases to type 1 diabetes listed in the 2018 ISPAD recommendations, in this outcome studied each one separately
|
From type 1 diabetes diagnostic to last news date, an average of 3 years
|
|
Presence of antibodies specific to an additional autoimmune disease at type 1 diabetes diagnostic
Time Frame: up to 3 weeks after type 1 diabetes diagnosis
|
Antibodies detected in the serum, antibodies specific to the following autoimmune diseases : Hashimoto (Thyroid peroxidase antibodies, and/or thyroglobulin antibodies) Graves disease (TRAK), coeliac disease (anti-tissue transglutaminase (tTG) antibodies,endomysial antibodies (EMA)), Addison disease ( adrenal antibodies ), autoimmune gastritis (parietal cell antibodies)
|
up to 3 weeks after type 1 diabetes diagnosis
|
|
Characteristics of patients, if at least one type of antibodies specific to an autoimmune disease is present or absent at type 1 diabetes diagnostic
Time Frame: up to 3 weeks after type 1 diabetes diagnosis
|
Family and personal history, biological, serological, anthropometrical characteristics at type 1 diabetes diagnostic
|
up to 3 weeks after type 1 diabetes diagnosis
|
|
Characteristics of patients, for each type of antibodies specific to an autoimmune disease, present or absent at type 1 diabetes diagnostic
Time Frame: up to 3 weeks after type 1 diabetes diagnosis
|
Family and personal history, biological, serological, anthropometrical characteristics at type 1 diabetes diagnostic
|
up to 3 weeks after type 1 diabetes diagnosis
|
|
Occurence or non-occurence of at least one type of antibody specific to an additional autoimmune disease
Time Frame: From type 1 diabetes diagnosis to last news date, from 1 to 6 years
|
Antibodies detected in the serum, antibodies specific to the following autoimmune diseases : Hashimoto (Thyroid peroxidase antibodies, and/or thyroglobulin antibodies) Graves disease (TRAK), coeliac disease (anti-tissue transglutaminase (tTG) antibodies,endomysial antibodies (EMA)), Addison disease ( adrenal antibodies ), autoimmune gastritis (parietal cell antibodies)
|
From type 1 diabetes diagnosis to last news date, from 1 to 6 years
|
|
Occurence or non-occurence of antibodies specific to each additional autoimmune disease listed in outcome 5
Time Frame: From type 1 diabetes diagnosis to last news date, from 1 to 6 years
|
Antibodies detected in the serum, antibodies specific to the following autoimmune diseases : Hashimoto (Thyroid peroxidase antibodies, and/or thyroglobulin antibodies) Graves disease (TRAK), coeliac disease (anti-tissue transglutaminase (tTG) antibodies,endomysial antibodies (EMA)), Addison disease ( adrenal antibodies ), autoimmune gastritis (parietal cell antibodies)
|
From type 1 diabetes diagnosis to last news date, from 1 to 6 years
|
|
Description of the characteristics of all the patients followed in our cohort of pediatric type 1 diabetes
Time Frame: Up to 3 weeks after type 1 diabetes diagnosis
|
Family and personal history, biological, serological, anthropometrical characteristics at type 1 diabetes diagnostic, presence of antibodies specific to an additional autoimmune disease, and occurence of additional autoimmune diseases
|
Up to 3 weeks after type 1 diabetes diagnosis
|
|
Description of the autoimmune characteristics of all the patients followed in our cohort of pediatric type 1 diabetes
Time Frame: during follow-up : From type 1 diabetes diagnosis to last news date, from 1 to 6 years
|
presence of antibodies specific to an additional autoimmune disease, and occurence of additional autoimmune diseases
|
during follow-up : From type 1 diabetes diagnosis to last news date, from 1 to 6 years
|
|
If detection of antibodies specific to an additional autoimmune disease : delay between detection of these antibodies and diagnosis of the corresponding autoimmune disease
Time Frame: From type 1 diabetes diagnosis to last news date, from 1 to 6 years
|
Antibodies detected in the serum, antibodies specific to the following autoimmune diseases : Hashimoto (Thyroid peroxidase antibodies, and/or thyroglobulin antibodies) Graves disease (TRAK), coeliac disease (anti-tissue transglutaminase (tTG) antibodies,endomysial antibodies (EMA)), Addison disease ( adrenal antibodies ), autoimmune gastritis (parietal cell antibodies)
|
From type 1 diabetes diagnosis to last news date, from 1 to 6 years
|
|
If patient diagnosed with Hashimoto when type 1 diabetes is diagnosed, proportion of patients with thyroid dysfunction
Time Frame: Up to 3 weeks after type 1 diabetes diagnosis
|
Thyroid dysfunction : hormonal dysfunction associated to Hashimoto
|
Up to 3 weeks after type 1 diabetes diagnosis
|
|
Occurence of thyroid dysfunction in patients with type 1 diabetes and Hashimoto
Time Frame: From type 1 diabetes diagnosis to last news date, from 1 to 6 years
|
Occurence during type 1 diabetes follow-up of thyroid dysfunction in patients with Hashimoto
|
From type 1 diabetes diagnosis to last news date, from 1 to 6 years
|
|
Proportion of patients with thyroid dysfunction due to Hashimoto needing a specific treatment
Time Frame: Up to 3 weeks after type 1 diabetes diagnosis
|
Up to 3 weeks after type 1 diabetes diagnosis
|
|
|
Occurence of specific treatment onset in patients followed for type 1 diabetes with thyroid dysfunction due to Hashimoto
Time Frame: From type 1 diabetes diagnosis to last news date, from 1 to 6 years
|
From type 1 diabetes diagnosis to last news date, from 1 to 6 years
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Carole LEGAGNEUR, MD, Centre Hospitalo-Universitaire de Nancy, Hôpital d'Enfants de Brabois
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Glucose Metabolism Disorders
- Metabolic Diseases
- Skin Diseases
- Immune System Diseases
- Eye Diseases
- Endocrine System Diseases
- Gastrointestinal Diseases
- Thyroid Diseases
- Intestinal Diseases
- Exophthalmos
- Orbital Diseases
- Goiter
- Hyperthyroidism
- Malabsorption Syndromes
- Pigmentation Disorders
- Hypopigmentation
- Adrenal Gland Diseases
- Adrenal Insufficiency
- Thyroiditis, Autoimmune
- Thyroiditis
- Diabetes Mellitus
- Diabetes Mellitus, Type 1
- Celiac Disease
- Autoimmune Diseases
- Vitiligo
- Hashimoto Disease
- Graves Disease
- Addison Disease
Other Study ID Numbers
Other Study ID Numbers
- 2020PI283
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.